Sanofi Chairman and acting CEO Serge Weinberg lays out criteria for a new top execeutive and said reports of a focus on French candidates stem from someone’s imagination.
The forced departure of CEO Chris Viehbacher does not augur significant changes in strategy at Sanofi, Chairman and interim CEO Serge Weinberg said Nov. 20.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
France’s simplification bill is a “first step” to improving the country’s clinical research environment, but more could be done to drive decentralized trials and simplify processes, says Leem, the French pharmaceutical industry association.
A new methodology for measuring pharmaceutical company carbon footprints could lead to a single standard for producing these calculations that is applicable to all medicines sold in France, said the industry association, Leem. However, it warned that there remains uncertainty about how the methodology will work in practice.
Some changes to the contentious social security financing bill have been made, but industry and the government remain at odds over a €1.2bn drugs overspend.
France’s health technology appraisal body, HAS, is putting more emphasis on the importance of economic evaluations in light of the rising costs of health technologies, including medicines and medical devices, and increasing budgetary pressures.
Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.
The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.
Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
